Traduction de «transactions 368 –240 608 other » (Néerlandais → Français) :

Cash flow used for investing activities –1 136 –2 842 1 706 Change in current and non-current financial debts 4 234 4 705 –471 Dividends paid to shareholders of Novartis AG –4 468 –3 931 –537 Treasury share transactions 368 –240 608 Other financing cash flows –112 –82 –30 Cash flow from financing activities 22 452 –430 Translation effect on cash and cash equivalents –21 –26 5 Change in cash and cash equivalents 2 172 –463 2 635 Cash and cash equivalents at January 1 2 894 2 038 856 Cash and cash equivalents at March 31 5 066 1 575 3 491
Variation des dettes financières à court et à long terme 4 234 4 705 –471 Dividendes payés aux actionnaires de Novartis AG –4 468 –3 931 –537 Transactions sur actions propres 368 –240 608 Autres flux de financement –112 –82 –30 Flux de trésorerie provenant des activités de financement 22 452 –430 Effet nets des écarts de conversion sur la trésorerie et les équivalents de trésorerie –21 –26 5

Algemene Regeling Regeling Zelfstandigen 2006 2007 2006 2007 LCM 60.326.798,63 47.486.080,73 6.266.259,82 5.085.773,27 LNM 5.206.579,90 4.890.264,72 276.152,28 346.860,96 NVSM 40.240.551,06 32.845.253,28 96.368,54 -86.699,61 LLM 7.281.949,69 7.940.140,72 1.000.143,60 1.026.262,18 MLOZ 16.029.306,89 11.466.608,33 1.118.783,82 853.774,54 HKZIV 2.531.189,83 1.728.429,65 65.549,24 64.307,30 NMBS 1.972.771,66 1.679.119,08 0,00 0,00 Totaal 133.589.147,66 108.035.896,51 8.823.257,30 7.290.278,64
Régime Général Régime Indépendant 2006 2007 2006 2007 ANMC 60.326.798,63 47.486.080,73 6.266.259,82 5.085.773,27 UNMN 5.206.579,90 4.890.264,72 276.152,28 346.860,96 UNMS 40.240.551,06 32.845.253,28 96.368,54 -86.699,61 UNML 7.281.949,69 7.940.140,72 1.000.143,60 1.026.262,18 MLOZ 16.029.306,89 11.466.608,33 1.118.783,82 853.774,54 CAAMI 2.531.189,83 1.728.429,65 65.549,24 64.307,30 SNCB 1.972.771,66 1.679.119,08 0,00 0,00 Total 133.589.147,66 108.035.896,51 8.823.257,30 7.290.278,64

TOTAAL V. I. 1 V. I. 2 V. I. 3 V. I. 4 V. I. 5 V. I. 6 V. I. 7 % vrouwen 20,452 47,965 83,819 -27,975 166,870 -481,159 -3 545,580 ouder dan 40 jaar -22,462 -34,896 41,450 286,000 -86,095 -229,247 -192,570 werkloosheid -410,985 64,793 782,191 140,518 -84,802 965,230 -2 590,930 openbare sector -44,032 66,295 -86,083 34,112 -46,667 -305,197 3 263,020 mortaliteit -168,869 1,081 313,608 348,736 -133,697 -169,388 -777,513 primaire ongeschiktheid -59,927 -271,079 262,368 157,325 -214,761 409,118 -1 233,100 urbanisatie (dichtheid) -85,085 20,651 49,536 -31,568 196,071 183,727 -136,459 urbanisatie (kwalitatief) -140,143 297,078 212,246 -2,538 -95,945 1,500 365,134 zorgverleners -240,973 314,925 -23,665 -68,933 795,469 306,530 -148,345 alle variabelen -1 152,024 506,813 1 635,470 835,677 496,443 681,114 -4 996,343 de variabelen in het KB -851,124 462,967 1 396,767 747,285 -84,265 -34,534 -3 614,898 variabelen KB + ongeschiktheid -911,051 191,888 1 659,135 904,610 -299,026 374,584 -4 847,998
TOTAL O.A. 1 O.A. 2 O.A. 3 O.A. 4 O.A. 5 O.A. 6 O.A. 7 % de femmes 20,452 47,965 83,819 -27,975 166,870 -481,159 -3 545,580 Plus de 40 ans -22,462 -34,896 41,450 286,000 -86,095 -229,247 -192,570 Chômage -410,985 64,793 782,191 140,518 -84,802 965,230 -2 590,930 Secteur public -44,032 66,295 -86,083 34,112 -46,667 -305,197 3 263,020 Mortalité -168,869 1,081 313,608 348,736 -133,697 -169,388 -777,513 Incapacité primaire -59,927 -271,079 262,368 157,325 -214,761 409,118 -1 233,100 Urbanisation (densité) -85,085 20,651 49,536 -31,568 196,071 183,727 -136,459 Urbanisation (qualitatif) -140,143 297,078 212,246 -2,538 -95,945 1,500 365,134 Prestataires de soins -240,973 314,925 -23,665 -68,933 795,469 306,530 -148,345 Toutes les variables -1 152,024 506,813 1 635,470 835,677 496,443 681,114 -4 996,343 Les variables de l'A.R. -851,124 462,967 1 396,767 747,285 -84,265 -34,534 -3 614,898 Variables A.R. + incapacité -911,051 191,888 1 659,135 904,610 -299,026 374,584 -4 847,998 Les facteurs de correction sont additifs par rapport aux variables sélectionnées.

0 0 0 0 392.491 2.875.489 3.867.104 N04BB01 AMANTADINE 39.603 41.705 45.979 48.640 48.240 46.207 46.524 N04BC01 BROMOCRIPTINE 1.743.567 1.430.796 1.103.419 793.889 600.713 457.563 365.866 N04BC02 PERGOLIDE 3.698.153 4.402.924 4.750.205 4.608.249 4.390.196 3.073.092 2.183.786 N04BC04 ROPINIROL 514.818 998.174 1.299.677 1.857.600 2.491.843 3.183.513 3.556.828 N04BC05 PRAMIPEXOL 1.989 442.008 1.372.432 2.108.926 2.616.501 3.430.619 3.914.049 N04BD01 SELEGILINE 1.735.757 1.672.997 1.528.522 1.439.033 1.429.377 1.341.368 1.232.290 N04BD02 RASAGILINE 0 0 0 0 0 0 40.692 N04BX01 TOLCAPON 0 0 0 0 0 0 8.519 N04BX02 ENTACAPON 218.632 1.259.895 2.051.947 2.670.294 3.152.974 2.187.780 1.883.580 TOTAAL 13.823.413 16.204.300 18.163.430 19.631.919 21.109.347 22.217.252 22.594.669
DE LA DECARBOXYLASE ET DE LA COMT 0 0 0 0 392.491 2.875.489 3.867.104 N04BB01 AMANTADINE 39.603 41.705 45.979 48.640 48.240 46.207 46.524 N04BC01 BROMOCRIPTINE 1.743.567 1.430.796 1.103.419 793.889 600.713 457.563 365.866 N04BC02 PERGOLIDE 3.698.153 4.402.924 4.750.205 4.608.249 4.390.196 3.073.092 2.183.786 N04BC04 ROPINIROLE 514.818 998.174 1.299.677 1.857.600 2.491.843 3.183.513 3.556.828 N04BC05 PRAMIPEXOLE 1.989 442.008 1.372.432 2.108.926 2.616.501 3.430.619 3.914.049 N04BD01 SELEGILINE 1.735.757 1.672.997 1.528.522 1.439.033 1.429.377 1.341.368 1.232.290 N04BD02 RASAGILINE 0 0 0 0 0 0 40.692 N04BX01 TOLCAPONE 0 0 0 0 0 0 8.519 N04BX02 ENTACAPONE 218.632 1.259.895 2.051.947 2.670.294 3.152.974 2.187.780 1.883.580 TOTAL 13.823.413 16.204.300 18.163.430 19.631.919 21.109.347 22.217.252 22.594.669

Net sales to third parties 12 578 12 578 11 086 Other revenues 242 242 204 Cost of Goods Sold -3 662 265 3 95 -3 299 -2 850 Gross profit 9 158 265 3 95 9 521 8 440 Marketing & Sales -3 202 1 -3 201 -2 863 Research & Development -2 548 14 593 -1 941 -1 781 General & Administration -539 -539 -542 Other income 97 2 99 82 Other expense -379 20 115 4 -240 -377 Operating income 2 587 280 618 210 4 3 699 2 959 Income from associated companies 368 107 -189 286 313 Financial income 27 27 51 Interest expense -188 -188 -173 Income before taxes 2 794 387 618 21 4 3 824 3 150 Taxes 5 -475 -678 -471 Net income 2 319 3 146 2 679
Eléments de Amortissements restructuration et T3 2010 d’immobilisations Pertes d’intégration liés Eléments T3 2010 T3 2009 Résultats IFRS incorporelles 1 de valeur 2 aux acquisitions 3 exceptionnels 4 Résultats core Résultats core 7 M USD M USD M USD M USD M USD M USD M USD Chiffre d’affaires net réalisé avec des tiers 12 578 12 578 11 086 Autres revenus 242 242 204 Coût des ventes -3 662 265 3 95 -3 299 -2 850 Marge brute 9 158 265 3 95 9 521 8 440 Marketing et vente -3 202 1 -3 201 -2 863 Recherche et développement -2 548 14 593 -1 941 -1 781 Administration et frais généraux -539 -539 -542 Autres produits 97 2 99 82 Autres charges -379 20 115 4 -240 -377 Résultat opérationnel 2 587 280 618 210 4 3 699 2 959 Quote-part dans le résultat net des entreprises associées 368 107 -189 286 313